You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. KAPS Biotech: A novel biomarker to improve prostate cancer diagnosis

    SBC: Kaps Biotechnology LLC            Topic: 102

    Abstract Prostate cancer (CaP) is the most common non-skin cancer in men and third most common cause of cancer deaths in men. Black men experience a higher burden of incidence and mortality from CaP compared to White men. The Prostate-Specific Antigen (PSA) test, a commonly used biomarker for early diagnosis and management of CaP, cannot alone accurately predict the presence of CaP, its aggressive ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement

    SBC: POLYNOVA CARDIOVASCULAR INC            Topic: NHLBI

    Project Summary: A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement Minimally invasive transcatheter aortic valve replacement (TAVR) has emerged as an effective therapy for the unmet clinical need of inoperable patients with severe aortic stenosis (AS). Recent longitudinal follow-up studies of TAVR patients however indicate that this procedure and associated technology may result i ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. An adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment

    SBC: POP Biotechnologies Inc.            Topic: NIAID

    Abstract Influenza is the cause of considerable morbidity and mortality globally. Certain groups, i.e., infants, pregnant young women, and older adults are especially at risk for severe disease. Despite immunization being the most effective and economical prophylactic approach, vaccines often provide less than optimal defense against an influenza illness, with efficacies ranging from 10-60%. This ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Portable, affordable, quantitative microchip electrophoresis system for integrated anemia and hemoglobin variant testing

    SBC: Hemex Health, Inc.            Topic: NHLBI

    PROJECT SUMMARY Anemia is characterized by low blood hemoglobin levels and has high prevalence affecting over one-third of the worldandapos;s population or about 2.5 billion people. Anemia has numerous causes, including nutritional deficiencies, oncologic conditions, and hematologic diseases, including hemoglobin gene variants. More than 7% of the worldandapos;s population carry hemoglobin gene va ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Clinical Text Automatic De-Identification to Support Large Scale Data Reuse and Sharing

    SBC: Clinacuity, Inc            Topic: 400

    The adoption of Electronic Health Record (EHR) systems is growing at a fast pace in the U.S., and this growth results in very large quantities of patient clinical data becoming available in electronic format with tremendous potential but an equally large concern for patient confidentiality breaches. Secondary use of clinical data is essential to fulfill the potential for high quality healthcare, i ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid Assessment of Drug Abuse from Municipal Wastewater by Smart Surface-Enhanced Raman Scattering Technique

    SBC: E-Lambda LLC            Topic: NIDA

    Rapid Assessment of Drug Abuse from Municipal Wastewater by Smart Surface-Enhanced RamanScattering Technique PROJECT SUMMARY Rapid assessment of drug abuse from municipal wastewater is a new strategy that can overcome many limitations of traditional surveillance technologies by providing a more rapid and objective measure of drug use, which can alert communities about raising problems in their ear ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. A PET Diagnostic for Imaging Bacterial Infection

    SBC: CHRONUS PHARMACEUTICALS, INC.            Topic: NIBIB

    PROJECT SUMMARY Bacterial infections such as those of prosthetic joints, bones (osteomyelitis) and heart valves (infective endocarditis) are difficult to diagnose and treat, and are a major cause of mortality, morbidity and health care costs. The long-term goal of our program is to develop a positron emission tomography (PET) radiotracer that can be used for non-invasive PET imaging to detect and ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Enabling self-reported outcomes for youth with developmental disabilities: The PediatricEvaluation of Disability Inventory- Patient Reported Outcome (PEDI-PRO)- Phase II

    SBC: ABLELINK TECHNOLOGIES INC            Topic: NICHD

    The lack of patient reported outcome measures (PROMs) appropriate for youth with neurodevelopmental disabilities (DD) and related cognitive impairments including Down syndrome (DS) poses a significant problem for healthcare research and practice. Parents and other professionals do not identify the same needs as youth, and failure to engage youth with DD in healthcare evaluation compromises healthc ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension

    SBC: Technology Commercialization Partners LLC            Topic: NHLBI

    ABSTRACT Pulmonary hypertension (PH) is a highly debilitating disease that affects about 1% of the global population, which increases up to 10% in individuals aged more than 65 years. The life expectancy for these patients is less than 10 years after diagnosis, and no specific drugs are available for pharmacologic treatment. Despite the introduction PDE5, prostacyclin analogs, and endothelin antag ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Treatment of Proliferative Vitreoretinopathy using Aerosolized Methotrexate

    SBC: POWERSCOPE, INC            Topic: NEI

    Project Summary Proliferative vitreoretinopathy (PVR) is a major complication of retinal detachments and is responsible for most of the failures in retinal reattachment surgeries. About 10% of retinal detachment patients suffer from PVR. These patients often have poor visual outcome despite multiple surgeries. Our previous work on inhibition of PVR has focused on pharmacological intervention concu ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government